InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent SystemGlobeNewsWire • Monday
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/24
InspireMD Congratulates CREST-2 Investigators on Completion of Trial EnrollmentGlobeNewsWire • 08/05/24
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6thGlobeNewsWire • 07/30/24
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024GlobeNewsWire • 05/28/24
InspireMD Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/24
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14thGlobeNewsWire • 05/07/24
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/03/24
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024GlobeNewsWire • 03/26/24
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/06/24
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6thGlobeNewsWire • 02/28/24
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection SystemGlobeNewsWire • 02/12/24
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory FrameworkGlobeNewsWire • 01/31/24
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North AmericaGlobeNewsWire • 01/03/24
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection SystemGlobeNewsWire • 12/20/23
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem LesionsGlobeNewsWire • 11/27/23
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a TurnaroundZacks Investment Research • 11/23/23
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/23